pyruvaldehyde has been researched along with Overweight in 5 studies
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.
methylglyoxal : A 2-oxo aldehyde derived from propanal.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Martino, D | 1 |
| Cappelletti, M | 1 |
| Tondo, M | 1 |
| Basello, K | 1 |
| Garbin, C | 1 |
| Speciani, A | 1 |
| Ferrazzi, E | 1 |
| Rabbani, N | 2 |
| Xue, M | 2 |
| Weickert, MO | 2 |
| Thornalley, PJ | 2 |
| Macías-Cervantes, MH | 1 |
| Rodríguez-Soto, JM | 1 |
| Uribarri, J | 1 |
| Díaz-Cisneros, FJ | 1 |
| Cai, W | 1 |
| Garay-Sevilla, ME | 1 |
| de Courten, B | 1 |
| de Courten, MP | 1 |
| Soldatos, G | 1 |
| Dougherty, SL | 1 |
| Straznicky, N | 1 |
| Schlaich, M | 1 |
| Sourris, KC | 1 |
| Chand, V | 1 |
| Scheijen, JL | 1 |
| Kingwell, BA | 1 |
| Cooper, ME | 1 |
| Schalkwijk, CG | 1 |
| Walker, KZ | 1 |
| Forbes, JM | 1 |
| Qureshi, S | 1 |
| Kandala, NB | 1 |
| Anwar, A | 1 |
| Waldron, M | 1 |
| Shafie, A | 1 |
| Messenger, D | 1 |
| Fowler, M | 1 |
| Jenkins, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Will Reduction in Dietary Advanced Glycation End- Products Reduce Chronic Low Grade Inflammation and Improve Insulin Sensitivity in Overweight and Obese Humans[NCT00422253] | 27 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.[NCT02095873] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Aortal pulse wave velocity is measured by a non-invasive oscillometric device. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
| Intervention | m/s (Median) | |
|---|---|---|
| Baseline | Post-8 weeks treatment | |
| Glyoxalase 1 Inducer | 7.9 | 8.0 |
| Placebo | 8.3 | 8.5 |
A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (> 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
| Intervention | mM h (Mean) | |
|---|---|---|
| Baseline | Post-8 weeks treatment | |
| Glyoxalase 1 Inducer | 10.8 | 9.9 |
| Placebo | 11.0 | 10.6 |
After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
| Intervention | number of capillaries per mm2 (Median) | |
|---|---|---|
| Baseline | Post-8 weeks treatment | |
| Glyoxalase 1 Inducer | 115 | 125 |
| Placebo | 119 | 128 |
Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
| Intervention | percentage of baseline value (Median) | |
|---|---|---|
| Baseline | Post-8 weeks treatment | |
| Glyoxalase 1 Inducer | 0.17 | 0.12 |
| Placebo | 0.18 | 0.26 |
4 trials available for pyruvaldehyde and Overweight
| Article | Year |
|---|---|
Reversal of Insulin Resistance in Overweight and Obese Subjects by
Topics: Adult; Blood Pressure; Body Mass Index; Carrier Proteins; Correlation of Data; Cross-Over Studies; D | 2021 |
Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Diet; Diet, Reducing; Energy Intake; Exercise | 2015 |
Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diet; Double-Blind Method; Female; Glucose Clamp Technique | 2016 |
Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Cell Line; Cross-Over Studies; Female; Gl | 2016 |
1 other study available for pyruvaldehyde and Overweight
| Article | Year |
|---|---|
Glycation-Driven Inflammation: COVID-19 Severity in Pregnant Women and Perinatal Outcomes.
Topics: COVID-19; Female; Glucose; Glycosylation; Humans; Infant, Newborn; Inflammation; Obesity; Overweight | 2022 |